129 related articles for article (PubMed ID: 35049443)
1. Role of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D6*14A and CYP2D6*14B.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Drug Metab Bioanal Lett; 2022; 15(1):51-63. PubMed ID: 35049443
[TBL] [Abstract][Full Text] [Related]
2. Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Naunyn Schmiedebergs Arch Pharmacol; 2019 Aug; 392(8):1015-1029. PubMed ID: 31025144
[TBL] [Abstract][Full Text] [Related]
3. Effects of G169R and P34S substitutions produced by mutations of CYP2D6*14 on the functional properties of CYP2D6 expressed in V79 cells.
Shiraishi T; Hosokawa M; Kobayashi K; Tainaka H; Yamaura Y; Taguchi M; Chiba K
Drug Metab Dispos; 2002 Nov; 30(11):1201-5. PubMed ID: 12386125
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition.
Niwa T; Murayama N; Yamazaki H
Curr Drug Metab; 2011 Jun; 12(5):412-35. PubMed ID: 21453270
[TBL] [Abstract][Full Text] [Related]
5. The Molecular and Enzyme Kinetic Basis for Altered Activity of Three Cytochrome P450 2C19 Variants Found in the Chinese Population.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Curr Mol Pharmacol; 2020; 13(3):233-244. PubMed ID: 31713493
[TBL] [Abstract][Full Text] [Related]
6. Functional evaluation of cytochrome P450 2D6 with Gly42Arg substitution expressed in Saccharomyces cerevisiae.
Tsuzuki D; Takemi C; Yamamoto S; Tamagake K; Imaoka S; Funae Y; Kataoka H; Shinoda S; Narimatsu S
Pharmacogenetics; 2001 Nov; 11(8):709-18. PubMed ID: 11692080
[TBL] [Abstract][Full Text] [Related]
7. Functional influence of human CYP2D6 allelic variations: P34S, E418K, S486T, and R296C.
Kim J; Lim YR; Han S; Han JS; Chun YJ; Yun CH; Lee CH; Kim D
Arch Pharm Res; 2013 Dec; 36(12):1500-6. PubMed ID: 23897164
[TBL] [Abstract][Full Text] [Related]
8. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.
Bertelsen KM; Venkatakrishnan K; Von Moltke LL; Obach RS; Greenblatt DJ
Drug Metab Dispos; 2003 Mar; 31(3):289-93. PubMed ID: 12584155
[TBL] [Abstract][Full Text] [Related]
9. In silico study on the inhibitory interaction of drugs with wild-type CYP2D6.1 and the natural variant CYP2D6.17.
Handa K; Nakagome I; Yamaotsu N; Gouda H; Hirono S
Drug Metab Pharmacokinet; 2014; 29(1):52-60. PubMed ID: 23857029
[TBL] [Abstract][Full Text] [Related]
10. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese.
Wang SL; Lai MD; Huang JD
Drug Metab Dispos; 1999 Mar; 27(3):385-8. PubMed ID: 10064570
[TBL] [Abstract][Full Text] [Related]
11. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.
Niwa T; Hiroi T; Tsuzuki D; Yamamoto S; Narimatsu S; Fukuda T; Azuma J; Funae Y
Brain Res Mol Brain Res; 2004 Oct; 129(1-2):117-23. PubMed ID: 15469888
[TBL] [Abstract][Full Text] [Related]
12. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M
Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory and Stimulatory Effects of Selective Serotonin Reuptake Inhibitors on Cytochrome P450 2D6-mediated Dopamine Formation from p-Tyramine.
Niwa T; Sugimoto S
J Pharm Pharm Sci; 2019; 22(1):585-592. PubMed ID: 31804922
[TBL] [Abstract][Full Text] [Related]
14. Site-Directed Mutagenesis of Cytochrome P450 2D6 and 2C19 Enzymes: Expression and Spectral Characterization of Naturally Occurring Allelic Variants.
Dong AN; Pan Y; Palanisamy UD; Yiap BC; Ahemad N; Ong CE
Appl Biochem Biotechnol; 2018 Sep; 186(1):132-144. PubMed ID: 29524040
[TBL] [Abstract][Full Text] [Related]
15. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
Hayhurst GP; Harlow J; Chowdry J; Gross E; Hilton E; Lennard MS; Tucker GT; Ellis SW
Biochem J; 2001 Apr; 355(Pt 2):373-9. PubMed ID: 11284724
[TBL] [Abstract][Full Text] [Related]
16. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17.
Shen H; He MM; Liu H; Wrighton SA; Wang L; Guo B; Li C
Drug Metab Dispos; 2007 Aug; 35(8):1292-300. PubMed ID: 17470523
[TBL] [Abstract][Full Text] [Related]
17. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.
Oscarson M; Hidestrand M; Johansson I; Ingelman-Sundberg M
Mol Pharmacol; 1997 Dec; 52(6):1034-40. PubMed ID: 9415713
[TBL] [Abstract][Full Text] [Related]
18. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
Zhou SF
Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
[TBL] [Abstract][Full Text] [Related]
19. Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles.
Bogni A; Monshouwer M; Moscone A; Hidestrand M; Ingelman-Sundberg M; Hartung T; Coecke S
Toxicol In Vitro; 2005 Aug; 19(5):621-9. PubMed ID: 15893449
[TBL] [Abstract][Full Text] [Related]
20. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
